The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
The company is bringing precision therapies for gynaecological cancers
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Subscribe To Our Newsletter & Stay Updated